Axcelead Drug Discovery Partners, Inc.’s Post

New report! 🔊 This week, Medicines Discovery Catapult, BioIndustry Association (BIA) and The Association of the British Pharmaceutical Industry (ABPI) have released The State of the Discovery Nation 2024 Report.   The report takes an in-depth look at the impact of the economy for companies in the life sciences sector, identifying key challenges and exploring the steps needed to break down these barriers to continue growing the UK medicines discovery pipeline 🔎   Prof. Chris Molloy, CEO of Medicines Discovery Catapult, said: “It is not enough to ask investors to simply become more comfortable with high-risk investments. We need to de-risk the innovation as much as we can.”   Discover more below 👇🏻

Behaviorally's Crispin Beale (Group President) will be speaking TOMORROW at #ContaminAzioni 2024 with Elma Research Italy in Milan! Join us to explore the evolution of market research and gain valuable insights into the pharmaceutical sector! Register here: https://hubs.ly/Q02wcBCZ0 #milan #conference #Elmaresearch #insights #insightsindustry #marketresearch #wearebehaviorally #behaviorallyinc

Drug development technology platform alliances are like few others in biopharma. Biren Shah, Jake Beverage of AbCellera, Amanda McAllister, PMP and Jonathan Kern of AbbVie, and Petra Sansom of Beam Therapeutics gave our readers a glimpse into the unique dynamics around partner selection, contract negotiations, IP sharing, and working group meeting frequency in the Q1 2024 #StrategicAllianceQuarterly. https://lnkd.in/gkZ5HjEk #alliancemanagement #alliances #strategicalliances #alliancemanagers #collaboration #strategicpartnerships #pharmaceutical #pharmaceuticalindustry #biopharma #biotech #biotechnology #biotechindustry #drugdevelopmentplatforms #drugdevelopmentplatform #drugdevelopment #drugdevelopmentplatformtechnology #drugdevelopment #innovation #drugdiscovery #drugdiscoveryscience

Ecosystems, coopetition, and cocreation. Sounds like a tech alliance, but believe it or not, we're talking strategic partnerships being formed around drug discovery technology platforms. Biren Shah, Jake Beverage of AbCellera, Amanda McAllister, PMP and Jonathan Kern of AbbVie, and Petra Sansom of Beam Therapeutics take us through the nuances of these collaborations in the Q1 2024 issue of #StrategicAllianceQuarterly. https://lnkd.in/gkzZvmUj

The pharmaceutical industry is being transformed by the integration of advanced technology, paving the way for new breakthroughs in drug discovery. With the rise of data-driven approaches and predictive modeling, previously insurmountable challenges are becoming opportunities for innovation. Our latest case study covers: ▶️ Challenges in CNS drug discovery and development and the innovative strategies that are overcoming them. ▶️ Data-driven approaches and predictive modeling that are enhancing accuracy and efficiency in drug development. Access the full report here ➡️ https://hubs.la/Q02LgZ6j0 #OGFormulation #DrugDiscovery #PharmaInnovation #CNSResearch #AdvancedTech Ardigen

‘How do I take advantage of and keep up with technology in pharmaceuticals?’ Innovation is at a crossroads, and technology is the new competitive frontier in the pharmaceutical industry. As we heard from Ray Pressburger at #Endpoints at #JPM24, pharma CEOs are concerned about keeping up with the pace of technology. How are you addressing your technology talent shortage and reset? #pharmaceuticals #technology #innovation #jpm2024 Endpoints News, Dr. Petra Jantzer, Kailash Swarna, Ben Ferrara, Joshua Taylor, Selen Karaca-Griffin, Aran Bahl, Tala Kayyali, Hannah Kanamori, Jake Stangl

SFBN Feed: BioMarin taps Amgen, Roche vets in executive reshuffle https://lnkd.in/g7inWmNT Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. BioMarin is recasting some of its executive team, announcing Wednesday the appointments of two pharmaceutical industry veterans to [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

Our portfolio company Aeovian Pharmaceuticals has initiated its Phase 1 clinical trial, marking a significant step in their journey. Alongside, the company has strengthened its leadership team and secured an additional $50 million in financing, showcasing robust support and confidence in its groundbreaking work: https://lnkd.in/gV6AVmx5 New US legislation is set to boost innovation in small molecule drug development, leading to more efficient and groundbreaking advancements in the pharmaceutical industry. Learn more about the impact of this legislation here: https://lnkd.in/ebG9-EYF An article published in Nature Portfolio discusses the potential of Generative AI (GenAI) in revolutionizing target identification in drug discovery. By assessing aging hallmarks and improving chemical syntheses, GenAI offers a new frontier in accelerating and refining the development of therapies for aging-related conditions: https://lnkd.in/epYVmPgf #ICYDK #ApolloVC #Lifespan #Healthspan #Longevity #VentureCapital

Want to learn more about the key trends to watch in pharma over the next year? Join me tomorrow for The Drugs That Will Shape 2024, sponsored by Avalere Health Register here - https://lnkd.in/eXd47Jv9 #pharma #biotech

BioMarin taps Amgen, Roche vets in executive reshuffle https://lnkd.in/gp3JCBjp Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. BioMarin is recasting some of its executive team, announcing Wednesday the appointments of two pharmaceutical industry veterans to [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News